@IronPig I don't think this applies to Imugene unfortunately.
The precision press release from August 2023 states "Imugene will assume ongoing clinical execution for azer-cel in the large B-cell lymphoma (LBCL) population who have relapsed following autologous CAR T treatment. The license also includes an option to develop up to three other cancer research programs in the future."
The announcement with TG Therapeutics is for "exclusive license to develop Azercabtagene Zapreleucel (azer-cel) for autoimmune diseases, and other indications outside of cancer"
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
-0.001(7.69%) |
Mkt cap ! $89.60M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.3¢ | 1.2¢ | $140.7K | 11.61M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 50 | 9000852 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 6923007 | 25 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |